Rezolute (RZLT) Q1 2027 earnings summary

Executive summary

• Ersodetug development advanced across tumor HI and congenital HI; upLIFT enrollment is complete, with topline results expected by mid-December 2026 and a BLA filing targeted for 2027 for one or both indications.

• FDA recommended a congenital HI BLA filing after reviewing additional data; the recommendation does not assure approval, and FDA has not determined approvability.

Financial highlights

• Net loss was $18.5M vs. $18.2M YoY; operating expenses were $19.4M vs. $19.8M, including R&D of $12.8M vs. $13.1M and G&A of $6.6M vs. $6.7M.

• Non-operating income was $0.9M vs. $1.7M; basic and diluted loss per share was $0.18 in both periods, and no revenue was generated.

• Cash, cash equivalents and marketable securities totaled $90.0M at September 30, 2026, vs. $107.8M at June 30, 2026; operating cash use was $18.8M.

Outlook and guidance

• Existing capital resources are expected to fund planned activities and contractual obligations for at least 12 months from issuance of the financial statements; additional financing will be needed for long-term requirements.

• upLIFT topline results are expected by mid-December 2026; the pre-BLA meeting was expected in H1 2027, with a BLA submission targeted for mid-2027.

• The sunRIZE open-label extension continues, with 56 participants remaining on treatment as of September 30, 2026.